Y-mAbs Therapeutics, Inc. (YMAB) shares are surging more than 48 percent on Friday morning trade after the company reported fourth-quarter profit of $1.157 million, compared to net loss of $36.89 million last year.
Total revenue for the quarter increased to $31.45 million from $9.59 million in the previous year.
Further, the company reiterated its financial guidance for 2023.
Currently, shares are at $5.23, up 58.97 percent from the previous close of $3.29 on a volume 4,082, 163.
For comments and feedback contact: editorial@rttnews.com
Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
